



---

## indacaterol / mometasone furoate 125 micrograms / 62.5 micrograms and 125 micrograms / 127.5 micrograms and 125 micrograms / 260 micrograms (Ateectura Breezhaler®)

09 April 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**indacaterol / mometasone furoate (Ateectura Breezhaler®)** is accepted for use within NHSScotland.

**Indication under review:** as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta<sub>2</sub>-agonists.

Indacaterol / mometasone furoate (Ateectura Breezhaler®) offers an additional treatment choice of inhaled corticosteroid (ICS) and long-acting beta<sub>2</sub>-agonist (LABA) in a single inhaler. SMC has previously accepted alternative LABA / ICS combinations for use in asthma.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 04 March 2021.*

**Chairman**  
**Scottish Medicines Committee**